
Publication|Articles|April 27, 2024
Peers & Perspectives in Oncology
- April II, 2024
- Pages: 60
Roundtable Roundup April: Renal Cell Carcinoma
Author(s)Targeted Oncology Staff
In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
Advertisement
CASE SUMMARY
- An African American woman aged 59 years presented with a left renal mass.
- She underwent left radical nephrectomy, which revealed clear cell RCC.
- Nine months later, she developed nodules in both lungs, mediastinum (35 × 38 mm), and retroperitoneal lymph nodes.
- Lung biopsy confirmed stage IV RCC with clear cell histology.
- Karnofsky performance status: 90%
- Hemoglobin: 11.1 g/dL
- Corrected calcium, neutrophils, and platelets: within normal limits
POLLING QUESTION
A decision was made to initiate systemic therapy. What frontline therapy are you most likely to choose for this patient?
Articles in this issue
about 2 years ago
Treating Rare Driver Mutations in NSCLC: EGFR Exon 20 InsertionsAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 ASCO Plenary Delivers Practice-Changing Progress
2
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
3
FDA Grants ODD to LRRC15-Targeting ADC SOT106 for Osteosarcoma
4
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
5








































